← Back to Search

Methylation-based Prognostic Assay for Barrett's Esophagus

N/A
Waitlist Available
Research Sponsored by Capsulomics, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 1 year
Awards & highlights
No Placebo-Only Group

Summary

This trial will see how new test results help doctors make decisions about monitoring and treating Barrett's esophagus.

Who is the study for?
This trial is for board-certified gastroenterologists in the U.S. who have been practicing for over 2 years, speak English, see at least 50 Barrett's esophagus patients a year, and have internet access. They should not have used the methylation assay test before.
What is being tested?
The study tests how doctors decide on surveillance and treatment for Barrett's esophagus when given educational materials about a new prognostic methylation-based assay developed by Capsulomics.
What are the potential side effects?
Since this trial involves educational materials rather than medical treatments or drugs, there are no direct physical side effects to participants.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~1 year
This trial's timeline: 3 weeks for screening, Varies for treatment, and 1 year for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Clinical performance change in physician behavior.
The impact of methylation assay on physician confidence in clinical care decision-making.

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Intervention GroupExperimental Treatment1 Intervention
The intervention group will receive standard-of-care clinical data for their virtual cases along with educational materials about the methylation assay. This group will then be provided with methylation assay data to be used in addition to clinical data.
Group II: Control GroupActive Control1 Intervention
The control group will receive standard-of-care clinical data for their virtual patient cases. No educational material on the methylation assay will be provided.

Find a Location

Who is running the clinical trial?

Capsulomics, Inc.Lead Sponsor

Media Library

Intervention Group Clinical Trial Eligibility Overview. Trial Name: NCT05846971 — N/A
Barrett's Esophagus Research Study Groups: Intervention Group, Control Group
Barrett's Esophagus Clinical Trial 2023: Intervention Group Highlights & Side Effects. Trial Name: NCT05846971 — N/A
Intervention Group 2023 Treatment Timeline for Medical Study. Trial Name: NCT05846971 — N/A
~21 spots leftby Nov 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top